Cargando…

Safety and tolerability of continuous inhaled iloprost in critically ill pediatric pulmonary hypertension patients: A retrospective case series

Inhaled iloprost (iILO) has shown efficacy in treating patients with hypoxic lung disease and pulmonary hypertension, inducing selective pulmonary vasodilation and improvement in oxygenation. However, its short elimination half‐life of 20–30 min necessitates frequent intermittent dosing (6–9 times p...

Descripción completa

Detalles Bibliográficos
Autores principales:	Colglazier, Elizabeth, Ng, Angelica J., Parker, Claire, Woolsey, David, Holmes, Raymond, Dsouza, Allison, Becerra, Jasmine, Stevens, Leah, Nawaytou, Hythem, Keller, Roberta L., Fineman, Jeffrey R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2023
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10507570/ https://www.ncbi.nlm.nih.gov/pubmed/37731624 http://dx.doi.org/10.1002/pul2.12289

Ejemplares similares

Hemodynamic assessment of transitioning from parenteral prostacyclin to selexipag in pediatric pulmonary hypertension
por: Colglazier, Elizabeth, et al.
Publicado: (2022)

Persistence of persistent pulmonary hypertension of the newborn: A case of de novo TBX4 variant
por: Tsoi, Stephanie M., et al.
Publicado: (2022)

Genetics dictating therapeutic decisions in pediatric pulmonary hypertension? A case report suggesting we are getting closer
por: Stevens, Leah, et al.
Publicado: (2022)

Pushing the envelope: a treat and repair strategy for patients with advanced pulmonary hypertension associated with congenital heart disease
por: Kameny, Rebecca Johnson, et al.
Publicado: (2017)

Inhaled iloprost for the control of pulmonary hypertension
por: Krug, Sabine, et al.
Publicado: (2009)

Inhaled iloprost for the treatment of patient with Fontan circulation
por: Kim, Yong Hyun, et al.
Publicado: (2014)

Rapid Transition from Inhaled Iloprost to Inhaled Treprostinil in Patients with Pulmonary Arterial Hypertension
por: Bourge, Robert C, et al.
Publicado: (2013)

Caveolin‐1 associated with severe (pediatric‐onset) presentation of pulmonary arterial hypertension
por: Farrell, Rachel, et al.
Publicado: (2022)

Review of inhaled iloprost for the control of pulmonary artery hypertension in children
por: Tissot, Cecile, et al.
Publicado: (2009)

Use of Inhaled Iloprost in an Infant With Bronchopulmonary Dysplasia and Pulmonary Artery Hypertension
por: Hwang, Seung-Kyung, et al.
Publicado: (2009)

Inhaled iloprost as third add-on therapy in idiopathic pulmonary arterial hypertension
por: Fernandes, Caio J.C.S., et al.
Publicado: (2021)

Inhaled iloprost is an effective alternative therapy for persistent pulmonary hypertension in newborns
por: Yıldırım, Şükran
Publicado: (2023)

Practice patterns of pulmonary hypertension secondary to left heart disease among pediatric pulmonary hypertension providers
por: Nawaytou, Hythem, et al.
Publicado: (2021)

Acute hemodynamic effect of inhaled iloprost in pulmonary artery hypertension evaluated with echocardiography
por: Loureiro, Maria José, et al.
Publicado: (2007)

Inhaled Iloprost for Patients With Precapillary Pulmonary Hypertension and Right-Side Heart Failure
por: Martischnig, Amadea M., et al.
Publicado: (2011)

Effects of inhaled iloprost on acute respiratory distress syndrome in prone and supine positions
por: Senturk, E, et al.
Publicado: (2009)

Survival with sildenafil and inhaled iloprost in a cohort with pulmonary hypertension: an observational study
por: Gall, Henning, et al.
Publicado: (2016)

Hemodynamic and gas exchange effects of inhaled iloprost in patients with COPD and pulmonary hypertension
por: Wang, Lan, et al.
Publicado: (2017)

Switching inhaled iloprost formulations in patients with pulmonary arterial hypertension: the VENTASWITCH Trial
por: Richter, Manuel J., et al.
Publicado: (2018)

Inhaled iloprost can improve oxygenation and shunt fraction in severe COVID-19
por: Serbanescu-Kele Apor de Zalán, Christiaan M.C., et al.
Publicado: (2022)

Phase Ib trial of inhaled iloprost for the prevention of lung cancer with predictive and response biomarker assessment
por: Miller, York E., et al.
Publicado: (2023)

Associated radiation exposure from medical imaging and excess lifetime risk of developing cancer in pediatric patients with pulmonary hypertension
por: Mahendra, Malini, et al.
Publicado: (2023)

Effects of inhaled iloprost on right ventriculovascular coupling and ventricular interdependence in acute pulmonary hypertension
por: Rex, S, et al.
Publicado: (2008)

Comparison of levosimendan, NO, and inhaled iloprost for pulmonary hypertension reversibility assessment in heart transplant candidates
por: Tavares‐Silva, Marta, et al.
Publicado: (2021)

Efficacy of Inhaled Iloprost in Cor Pulmonale and Severe Pulmonary Hypertension Associated with Tuberculous Destroyed Lung
por: Park, Yae Min, et al.
Publicado: (2014)

The optimization of iloprost inhalation under moderate flow of oxygen therapy in severe pulmonary arterial hypertension
por: Nakayama, Kazuhiko, et al.
Publicado: (2018)

Inhaled iloprost improves gas exchange in patients with COVID-19 and acute respiratory distress syndrome
por: Tsareva, Natalia A., et al.
Publicado: (2021)

Patent ductus arteriosus and the risk of bronchopulmonary dysplasia-associated pulmonary hypertension
por: Nawaytou, Hythem, et al.
Publicado: (2023)

Lung vasodilatory response to inhaled iloprost in experimental pulmonary hypertension: amplification by different type phosphodiesterase inhibitors
por: Schermuly, Ralph Theo, et al.
Publicado: (2005)

Postablation Right Atrial Dissection in Ebstein's Anomaly
por: Hassan, Fatemat, et al.
Publicado: (2017)

Hyperbaric Oxygen Therapy with Iloprost Improves Digit Salvage in Severe Frostbite Compared to Iloprost Alone
por: Magnan, Marie-Anne, et al.
Publicado: (2021)

Digital Tracking of Physical Activity, Heart Rate, and Inhalation Behavior in Patients With Pulmonary Arterial Hypertension Treated With Inhaled Iloprost: Observational Study (VENTASTEP)
por: Stollfuss, Barbara, et al.
Publicado: (2021)

Acute response to rapid iloprost inhalation using the Breelib™ nebulizer in pulmonary arterial hypertension: the Breelib™ acute study
por: Richter, Manuel J., et al.
Publicado: (2019)

Iloprost for COVID-19-related vasculopathy
por: Moezinia, Carine J, et al.
Publicado: (2020)

Higher body mass index is associated with a lower iloprost infusion rate tolerance and higher iloprost-related adverse events in patients with systemic sclerosis
por: Bixio, Riccardo, et al.
Publicado: (2022)

A multicenter, retrospective study of patients with pulmonary arterial hypertension transitioned from parenteral prostacyclin therapy to inhaled iloprost
por: Channick, Richard N., et al.
Publicado: (2013)

Effects of intraoperative inhaled iloprost on primary graft dysfunction after lung transplantation: A retrospective single center study
por: Lee, Su Hyun, et al.
Publicado: (2016)

Acute Iloprost Inhalation Improves Right Ventricle Function in Pulmonary Artery Hypertension: A Cardiac Magnetic Resonance Study
por: Li, Jing-Hui, et al.
Publicado: (2019)

Inhaled iloprost induces long‐term beneficial hemodynamic changes in patients with pulmonary arterial hypertension receiving combination therapy
por: Yasuda, Kenichiro, et al.
Publicado: (2022)

The Use of an Inspiration-Synchronized Vibrating Mesh Nebulizer for Prolonged Inhalative Iloprost Administration in Mechanically Ventilated Patients—An In Vitro Model
por: Otto, Matthias, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_bhjllu621jimdsr52d9i0aqcjn